Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.41 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RGS4 | P49798 | 1/20 | 0.32 |
| ▸ | RGS8 | P57771 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MPI | P34949 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13006860 | 0.81 | KDM4E (0.40) | BRD9BRD7MEN1GLAKMT2A | |
| SCHEMBL14505623 | 0.81 | BRD9 (0.36) | BRD9BRD7MEN1GLAKMT2A | |
| SCHEMBL14505470 | 0.79 | BRD9 (0.38) | BRD9BRD7MEN1KMT2AKDM4E | |
| SCHEMBL10138649 | 0.78 | DHODH (0.32) | BRD9DHODHKDM4E | |
| SCHEMBL15782229 | 0.78 | CDK1 (0.33) | BRD9MAPT | |
| SCHEMBL13236720 | 0.78 | SIRT1 (0.41) | RGS4RGS8ADORA2AKDM4ENPC1 | |
| SCHEMBL24665897 | 0.75 | PLA2G7 (0.34) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL14533426 | 0.72 | MAPK1 (0.31) | BRD9KDM4ENPC1TDP2ABL1 | |
| SCHEMBL14505510 | 0.70 | BRD9 (0.37) | BRD9BRD7MEN1GLAKMT2A | |
| SCHEMBL14505843 | 0.68 | PDE5A (0.40) | BRD9BRD7MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059665-A1 | DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-8183351-B2 | Avermectin derivatives | BAYER CROPSCIENCE AG (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183351-B2 | Avermectin derivatives | BAYER CROPSCIENCE AG (DE) | 2012-05-22 | — | — | US | disclosed |
| US-7932283-B2 | Fungicide N-cyclopropyl-sulfonylamide derivatives | BAYER CROPSCIENCE AG (DE) | 2011-04-26 | — | — | US | disclosed |
| US-7855166-B2 | Sulfonylamino(thio)carbonyl compounds | BAYER CROPSCIENCE GMBH (DE) | 2010-12-21 | — | — | US | disclosed |
| US-7855166-B2 | Sulfonylamino(thio)carbonyl compounds | BAYER CROPSCIENCE GMBH (DE) | 2010-12-21 | — | — | US | disclosed |
| US-20100234312-A1 | AVERMECTIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234312-A1 | AVERMECTIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20090137611-A1 | Fungicide N-Cyclopropyl-Sulfonylamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2009-05-28 | — | — | US | disclosed |
| US-RE39607-E1 | Herbicidal sulphonylamino(thio) carbonyl compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-01 | — | — | US | disclosed |
| US-RE39607-E1 | Herbicidal sulphonylamino(thio) carbonyl compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | BRD9 4854/4885BRD7 4646/4885MEN1 1095/4885 |
| US-20100234312-A1 | AVERMECTIN DERIVATIVES | OXTR, C3AR1, CBR3 | BRD9 1905/4885BRD7 2088/4885MEN1 1918/4885 |
| US-20090137611-A1 | Fungicide N-Cyclopropyl-Sulfonylamide Derivatives | CYP51A1, ERG28, CBR3 | BRD9 2969/4885BRD7 1998/4885MEN1 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.